CO2022008968A2 - Nuevos derivados de metilquinazolinona - Google Patents

Nuevos derivados de metilquinazolinona

Info

Publication number
CO2022008968A2
CO2022008968A2 CONC2022/0008968A CO2022008968A CO2022008968A2 CO 2022008968 A2 CO2022008968 A2 CO 2022008968A2 CO 2022008968 A CO2022008968 A CO 2022008968A CO 2022008968 A2 CO2022008968 A2 CO 2022008968A2
Authority
CO
Colombia
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
CONC2022/0008968A
Other languages
English (en)
Inventor
Cosimo Dolente
David Stephen Hewings
Daniela Krummenacher
Piergiorgio Francesco Tommaso Pettazzoni
Juergen Wichmann
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2022008968A2 publication Critical patent/CO2022008968A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

la invención proporciona un compuesto novedoso que tiene la fórmula general (i) o una sal farmacéuticamente aceptable de este. el compuesto de fórmula (i) se puede utilizar como medicamento.
CONC2022/0008968A 2019-12-10 2022-06-28 Nuevos derivados de metilquinazolinona CO2022008968A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (1)

Publication Number Publication Date
CO2022008968A2 true CO2022008968A2 (es) 2022-07-19

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008968A CO2022008968A2 (es) 2019-12-10 2022-06-28 Nuevos derivados de metilquinazolinona

Country Status (18)

Country Link
US (1) US20220298119A1 (es)
EP (1) EP4073065A1 (es)
JP (2) JP7108146B2 (es)
KR (1) KR20220110554A (es)
CN (1) CN114787156A (es)
AR (1) AR122351A1 (es)
AU (1) AU2020403443B2 (es)
BR (1) BR112022011123A2 (es)
CA (1) CA3162883A1 (es)
CL (1) CL2022001529A1 (es)
CO (1) CO2022008968A2 (es)
CR (1) CR20220251A (es)
IL (1) IL292161A (es)
MX (1) MX2022006783A (es)
PE (1) PE20221778A1 (es)
TW (1) TW202136245A (es)
WO (1) WO2021116055A1 (es)
ZA (1) ZA202204675B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351577A1 (en) * 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG Combination therapy for cancer treatment
AU2022290823A1 (en) * 2021-06-09 2023-12-07 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2022258600A1 (en) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022383040A1 (en) 2021-11-04 2024-03-07 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2024017294A1 (zh) * 2022-07-19 2024-01-25 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US9814714B2 (en) * 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
IL292161A (en) 2022-06-01
CL2022001529A1 (es) 2023-02-10
CN114787156A (zh) 2022-07-22
AR122351A1 (es) 2022-09-07
MX2022006783A (es) 2022-07-11
BR112022011123A2 (pt) 2022-08-23
PE20221778A1 (es) 2022-11-16
TW202136245A (zh) 2021-10-01
AU2020403443B2 (en) 2023-02-23
US20220298119A1 (en) 2022-09-22
EP4073065A1 (en) 2022-10-19
CR20220251A (es) 2022-07-11
ZA202204675B (en) 2022-12-21
AU2020403443A1 (en) 2022-05-12
WO2021116055A1 (en) 2021-06-17
JP2022531609A (ja) 2022-07-07
KR20220110554A (ko) 2022-08-08
CA3162883A1 (en) 2021-06-17
JP2022124458A (ja) 2022-08-25
JP7108146B2 (ja) 2022-07-27

Similar Documents

Publication Publication Date Title
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2020003219A1 (es) Compuestos
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
UY35362A (es) Compuestos terapéuticos
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CO2021016504A2 (es) Inhibidores de cdk
AR121226A1 (es) Compuestos y usos de estos
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
UY37941A (es) Derivados de bencimidazol y sus usos
CO2021008681A2 (es) Inhibidor de 15-pgdh
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
CO2021017202A2 (es) Compuestos tricíclicos